PRINCETON, N.J.--(BUSINESS WIRE)--Celator Pharmaceuticals today announced new data on previously untreated elderly patients with acute myeloid leukemia (AML) and multiple-risk factors treated with CPX-351 (cytarabine:daunorubicin) Liposome Injection. An analysis of results from a randomized Phase 2b clinical study showed that CPX-351, already reported to be highly active in all patient subgroups, produced the greatest benefits in response rate and reduction in 60-day mortality compared to standard therapy in patients with secondary AML and adverse cytogenetics. The findings were presented at the 54th American Society of Hematology (ASH) Annual Meeting being held in Atlanta, Georgia (ASH Abstract #3626).